Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics
adherence; compliance-HIV; time history of drug intake; PI concentration in plasma; drug dosing regimens; once-daily dosing; twice-daily dosing; pharmacokinetics; pharmacodynamics; systems therapeutics
Abstract :
[en] Once-daily dosing almost invariably shows a slightly higher percentage of prescribed doses taken than does twice-daily dosing. Many pharmaceutical scientists, regulators, and prescribers have considered this finding to signify the therapeutic superiority of once-daily dosing. The therapeutically more relevant question, however, is not the percentage of prescribed doses taken but the comparative impact of missed doses on the pharmacologic effects of a drug under the two dosing regimens. A key point in this regard is that the pharmacokinetic equivalent of a single missed once-daily dose is 2-3 sequentially omitted twice-daily doses. Thus, an important parameter in comparing the two regimens is the probability of two or three twice-daily doses being sequentially omitted, versus the probability of missing a single once-daily dose. Our data indicate that the probability of sequential omission of 2-3 twice daily doses is half the probability of omission of a single once-daily dose. For that reason, a twice-daily regimen could prove to be superior to a once-daily regimen in maintaining drug concentrations within a therapeutically desirable range. A more important consideration, however, is to maintain not just the concentration of drug in plasma, but the drug's therapeutic action. The duration of therapeutic drug action following a last-taken dose is not only drug-specific, but also, for some drug, dependent on the pharmacodynamic properties. Judging the comparative superiority of one dosing regimen over another requires knowledge of the drug's duration action after a last-taken dose, plus knowledge of the comparative probabilities of the various patterns of dose omission. When applied to HIV protease inhibitors, a twice-daily regimen appears to be better than an once-daily regimen in maintaining therapeutically effective drug actions.
Comté, Laetitia ; Université de Liège - ULiège > Département de mathématique > Statistique (aspects expérimentaux)
Vrijens, Bernard ; Université de Liège - ULiège > Département de mathématique
Tousset, Eric; Pharmionic Research Center
Gérard, Paul ; Université de Liège - ULiège > Département de mathématique > Statistique (aspects expérimentaux)
Urquhart, John; University of California, San Francisco Medical Center > Department of Biopharmaceutical Sciences > Center for Drug Development Science
Language :
English
Title :
Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics
Publication date :
August 2007
Journal title :
Journal of Pharmacokinetics and Pharmacodynamics
ISSN :
1567-567X
eISSN :
1573-8744
Publisher :
Springer/Plenum Publishers, New York, United States - New York
Moyle G (2002) The appt-1 study: assessing patients preferred treatments. Program and abstracts of the 6th International Congress on Drug Therapy in HIV Infection. November 17-21, Glasgow, Scotland, Abstract p 90
Hughes D (2006). Less is more: medicines that require less frequent administration improve adherence, but are they better?. Pharmacoeconomics 24(3): 211-213
Claxton AJ, Cramer J and Pierce C (2001). A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23(8): 1296-1310
Vrijens B and Urquhart J (2005). Patient adherence to prescribed antimicrobial drug dosing regimens. J Antimicrob Chemother 55(5): 616-627
Vrijens B, Tousset E, Rode R, Bertz R, Mayer S and Urquhart J (2005). Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol 45(4): 461-467
Vrijens B, Tousset E, Gaillard P-A, Metry JM and Urquhart J (2005). Major features of dose omissions in 87 ambulatory drug trials. Clin Pharmacol Ther 77(2): 99
Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM and Singh N (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133: 21-30
Paterson DL, Potoski B and Capitano B (2002). Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr 31(Suppl 3): S103-S106
Vrijens B and Goetghebeur E (1997). Comparing compliance patterns between randomized treatments. Control Clin Trials 18(3): 187-203
Bertz R, Renz C, Foit C, Swerdlow J, Ye X, Jasinsky O, Hsu A, Granneman GR, Sun E (2001) Steady-state pharmacokinetics of Kaletra (lopinavir/ritonavir 400/100 mg BID) in HIV-infected subjects when taken with food. Second International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, The Netherlands
Kaletra® Prescribing Information, Abbott Laboratories, January (2002)
Urquhart J and Vrijens B (2005). New findings about patient adherence to prescribed drug dosing regimens: an introduction to pharmionics. EJHP 5: 103-106